Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master TrialAmy Burd, John C. Byrd, Ross L. Levine et al.|Nature Medicine|2020Cited by 195
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022Peter L. Greenberg, Cindy Hochstetler, Bhumika J. Patel et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 126
Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b StudyJacqueline S. Garcia, Guillermo Garcia‐Manero, Andrew H. Wei et al.|Blood|2020Cited by 58
Myelodysplastic Syndromes, Version 2.2015Peter L. Greenberg, Courtney Smith, Richard M. Stone et al.|Journal of the National Comprehensive Cancer Network|2015Cited by 54
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic SyndromeAndrew H. Wei, Meagan A. Jacoby, Jacqueline S. Garcia et al.|Blood|2019Cited by 46